SUNNYVALE, Calif.--(BUSINESS WIRE)--BioImagene, the leading provider of innovative digital pathology solutions, announced today that the company is advancing its goal of bridging personalized medicine and the clinical practice of pathology by providing Companion AlgorithmsTM. These specialized algorithms, which BioImagene develops for use with its VirtuosoTM suite of web-based software, aid pathologists in the quantitative assessment of specialized diagnostic tests used to determine patient suitability for specific cancer therapies. As pharmaceutical companies work to develop companion diagnostics to individualize therapy for cancer patients, Companion Algorithms further enable pathologists to correctly identify and accurately measure specific biomarkers used to determine appropriate treatment options for patients.
